Prothena Stock News

Prothena Co. plc (NASDAQ:PRTA) CAO Karin L. Walker sold 4,519 shares of the companys stock in a transaction that occurred on Tuesday, November 23rd. The shares were sold at an average price of $57.88, for a total value of $261,559.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is []

AQR Capital Management LLC purchased a new stake in shares of Prothena Co. plc (NASDAQ:PRTA) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,917 shares of the biotechnology companys stock, valued at approximately $253,000. A number of other large investors have also modified []

JMP Securities started coverage on shares of Prothena (NASDAQ:PRTA) in a report issued on Friday morning, PriceTargets.com reports. The firm issued an outperform rating and a $77.00 target price on the biotechnology companys stock. PRTA has been the topic of several other research reports. Royal Bank of Canada upped their target price on shares of []

Prothena Co. plc (NASDAQ:PRTA) gapped up before the market opened on Friday . The stock had previously closed at $54.59, but opened at $56.69. Prothena shares last traded at $59.19, with a volume of 1,082 shares. A number of brokerages have issued reports on PRTA. Zacks Investment Research downgraded Prothena from a buy rating to []

Prothena Corporation plc (NASDAQ:PRTA)s traded shares stood at 0.35 million during the last session, with the companys beta value hitting 1.21. At the close of trading, the stocks price was $58.73, to imply an increase of 7.58% or $4.14 in intraday trading. The PRTA shares 52-week high remains $79.75, putting it -35.79% down since that Boom Or Bust: Where Is Prothena Corporation plc (NASDAQ: PRTA) Stock Headed Next? Read More »

Prothena Co. plc (NASDAQ:PRTA) insider Michael J. Malecek sold 10,000 shares of the businesss stock in a transaction on Friday, November 19th. The stock was sold at an average price of $55.00, for a total transaction of $550,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through []

Within the last quarter, Prothena Corp (NASDAQ: PRTA ) has observed the following analyst ratings:

Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.

Charles Schwab Investment Management Inc. lifted its holdings in shares of Prothena Co. plc (NASDAQ:PRTA) by 11.0% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 206,826 shares of the biotechnology company’s stock after buying an additional 20,435 shares during the period. Charles Schwab Investment Management […]

Related Stocks: INTU , CROX , BX , BOOT , PRTA , HCA , DDS , SPLG , XLE , STLD , DELL , ALLY , TGT , EL ,

An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why

Prothena misses on earnings and revenues in the third quarter of 2021. Nevertheless, the company's progress with its AD pipeline is encouraging.

Prothena (PRTA) delivered earnings and revenue surprises of -5.33% and -0.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. The post 7 A-Rated Healthcare Stocks to Buy for the Long Haul appear

VRTX vs. PRTA: Which Stock Is the Better Value Option?